



1635

RECEIVEL

0/I. D.S

EFS ID:

23299

Application ID:

10080794

Title of Invention:

TRPM-2 Antisense Therapy USing an Oligonucleotide Having 2'-O-

(2-methoxyethyl) modifications

First Named Inventor:

Martin Gleave

Domestic/Foreign Application:

Domestic Application

Filing Date:

2002-02-22

Effective Receipt Date:

2003-02-14

Submission Type:

Information Disclosure Statement

Filing Type:

null

Confirmation Number:

2924

Attorney Docket Number:

UBC.P-020-3

cn=Marina T. Larson, ou=Registered Attorneys, ou=Patent and

Digital Certificate Holder:

Trademark Office, ou=Department of Commerce, o=U.S.

Government, c=US

Certificate Message Digest:

f/0w03VQX1YjCkuD7zBj6g==



TRANSMITTAL FORM

Electronic Version 1.0.3

Application

10/080,794

Number:

Attorney Docket UBC.P-020-

Number:

DC.1 -020

Stylesheet Version: 1.0

Submission Type: Information

Disclosure Statement

TRPM-2 Antisense Therapy USing an Oligonucleotide Having 2'-O-(2-methoxyethyl) modifications

First Named Inventor: Martin Gleave

SUBMITTED BY

Name:

Dr. Marina T. Larson

Registration Number:

32,038

Electronic Signature

Mark: //marina//

Date Signed: 20030214

I certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Attached Files:

us-information-disclosure-statement

idsids.xml

Comments:

App_ID=10080794 Page 2 of 2